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Abstract
Background: There is accumulating evidence from the
epidemiological field of telomere biology that telo-
mere length plays an important role in the pathophy-
siology of cardiovascular disease. The RNA-depen-
dent DNA polymerase, telomerase, is essential in
regulating telomere length by acting as a reverse
transcriptase. However, the relationship between telo-
merase activity and telomere length in cardiovascular
disease is unclear. This is due, in part, to the paucity
of information on the utility of a quantitative and rou-
tine assay for the determination of telomerase activity
in circulating blood leukocytes.
Methods: We used a validated, high-sensitive real-
time quantitative telomeric repeat amplification pro-
tocol (RQ-TRAP) to determine telomerase activity in
circulating blood leukocytes.
Results: The present investigation demonstrated
direct and reliable detection of telomerase activity of
circulating blood leukocytes.
Conclusion: The present investigation suggests the
feasibility of using RQ-TRAP assay in routine screen-
ing of telomerase activity in blood specimens typical-
ly collected in a clinical/epidemiological setting.
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Introduction
The telomere-telomerase complex plays an important
role in human disorders including cardiovascular
disease (1) and carcino/tumorigenesis (2, 3). Critical
shortening of the telomere is prevented by telome-
rase activity that consists of de novo synthesis of telo-
meric DNA. Population-based studies of telomere
length can help obtain additional information on
factors directly influencing telomere length, such as
telomerase activity. Various methods are used for the
determination of telomerase activity in association
with germline, immortal, and activated (including
tumor) cells. However, at present, routine detection of
telomerase activity in mammalian/somatic cells
(including circulating human leukocytes) in a popu-
lation-based setting is rare, owing to its low basal
activity.
Very low levels of telomerase activity have been
observed in circulating mononuclear blood cells from
otherwise healthy subjects using qualitative and
semi-quantitative assays (4–7). The telomeric repeat
amplification protocol (TRAP), using polyacrylamide
gel and radioactivity to detect telomerase activity in
leukocytes, does not have the sensitivity to detect
basal levels (4, 5). Also, it is not adequate for pro-
cessing large number of samples as required for epi-
demiological studies. The semi-quantitative assay,
TRAP-ELISA, has also been used in protein extracts
from circulating mononuclear blood cells from
patients with hepatocellular carcinoma and healthy
subjects, showing an association of telomerase activ-
ity with hepatocellular cancer (6, 7).
Recently, a real-time quantitative SYBR Green high-
sensitivity telomeric repeat amplification protocol
(RQ-TRAP) for rapid quantitation of telomerase activ-
ity has been developed (8, 9). This procedure may
serve as an alternative for the study of telomerase
regulation and its relevance to somatic cell physio-
logy, particularly in population studies. Furthermore,
the sensitivity of the RQ-TRAP assay has been dem-
onstrated to be greater than the TRAP-ELISA assay
(9). We evaluated the applicability/utility of RQ-TRAP
to determine telomerase activity in circulating human
leukocytes in blood samples collected in a manner
that mimics routine blood collection/storage typically
performed for clinical/epidemiological investigations.
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Table 1 Cycle thresholds (Ct) for telomerase activity of the cell extracts.
Samples Ct (mean"SE)
Day 0 Day 1 Day 3 Dayq10 (frozen)*
Participant 1 27.62"0.12 29.19"0.07 28.31"0.14 28.66"0.02
Participant 1 HI 39.54"0.11 34.29"0.53 34.36"0.79 34.22"0.89
Participant 2 27.36"0.10 29.62"0.53 28.91"0.09 27.18"0.40
Participant 2 HI 37.81"1.08 36.54"2.37 38.14"1.13 36.86"2.03
Participant 3 28.80"0.24 27.49"0.20 28.35"0.23 28.99"0.14
Participant 3 HI 35.25"0.86 36.87"1.25 36.11"1.52 35.36"1.00
Whole blood was kept at 48C at all times and prepared for quantitative telomerase detection (QTD) at day 0, day 1, and day
3. The Ct was set at 0.05. Each sample was evaluated in duplicate and the heat inactivated (HI) results are presented. Lower
Ct indicates higher telomerase activity. *The buffy coat was frozen at day 0.
Figure 1 Standard curve of TSR control template with serial
dilution.
Each concentration of the control template was analyzed in
duplicate.
Materials and methods
Blood sample collection
Peripheral blood was collected from three unrelated, healthy
volunteers at the Children’s Hospital Boston, MA, USA. All
volunteers were male, aged between 32 and 44 years and
gave informed consent. The procedures were approved by
the Committee for the Protection of Human Subjects at
Children’s Hospital Boston. Four heparin tubes, each con-
taining 2 mL of blood, were drawn from each participant. To
mimic delivery of blood specimens obtained for population-
based studies, buffy coats were processed as follows: the
buffy coat of the first blood tube was isolated and processed
immediately, the buffy coat of the second blood tube was
isolated after overnight storage at 48C, the buffy coat of the
third tube was isolated after weekend (3-day) storage at 48C,
and the buffy coat of the fourth tube was isolated immedi-
ately after blood drawn and then stored at –808C for at least
10 days before processing. To further evaluate the effect of
long-term storage on telomerase activity, a frozen buffy coat
was stored at –808C for over 1 year (1-year BC). Leukocytes
were counted using the Advia 120 Hematology
Analyzer (Bayer Diagnostic Division, Tarrytown, NY, USA).
RQ-TRAP assay
Cell extracts for telomerase activity assays were prepared
following manufacturer’s instructions (Allied Biotech, Inc.,
Ijamsville, MD, USA). In brief, cells were lysed in 1X lysis
buffer and incubated at 48C for 30 min. The lysate was then
centrifuged at 12,000=g for 20 min at 48C, and the super-
natant collected. The protein concentration of the cell lysate
was determined using the bicinchoninic acid (BCA) protein
assay (Thermo Fisher Scientific Inc., Rockford, NY, USA)
according to the manufacturer’s instructions. Telomerase
activity was determined using the quantitative telomerase
detection (QTD) kit (Allied Biotech, Inc., Ijamsville, MD, USA),
an optimized and previously validated SYBR Green real-time
PCR method, according to the manufacturer’s protocol. Stan-
dards, inactivated samples and no-template-reactions were
also assayed on every plate for quality control purposes,
and to minimize inter-plate variability. A serial dilution-
calibration curve was also performed on each plate to further
minimize inter-plate variability, as recommended by the
manufacturer. Each sample was analyzed in duplicate as
described previously (9). Melting curve analysis was per-
formed on each run to verify specificity and identity of the
PCR products. All real-time amplifications were performed
on an ABI Prism 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). Telomerase activity was
expressed relative to telomere short repeat (TSR) control
template, and interpreted relative to 293T cells (a trans-
formed human renal epithelial cell line) as per the manufac-
turer’s specifications.
Results
The average total-cell count (mean"SE, ns12) for
all participants was 1236"64, and the average cell
distributions (%"SE, ns12) for neutrophils, eosino-
phils, basophils, lymphocytes, and monocytes were
52.6"2.0, 6.4"0.5, 0.9"0.2, 24.4"1.5, and 8.5"0.5,
respectively. The mean protein concentration (mean"
SE, ns12) of the cell lysate was 1.073"0.030 g/L.
Table 1 shows the cycle thresholds (Ct) for leuko-
cyte extracts processed at day 0, 1, 3, and q10 time-
points. In addition, the Ct for the 1-year BC lysate was
(mean"SE) 27.4"0.5. Of note, these Ct values were
comparable across the various time-points that they
were analyzed. The heat-inactivated (HI) leukocyte
extracts and no-template-control reactions consis-
tently exhibited a Ct of 35 cycles or higher, or null-
amplification (at least )5.6 cycles as compared to the
respective active lysate) (Table 1). Our observed con-
trol-Cts were within the range specified by the manu-
facturer of 33 cycles for the blank assay and virtually
identical to those reported previously (9). The corre-
lation coefficient (R2) for the TSR control calibration
curve with serial dilution was 0.997 (Figure 1). The
inter-assay variability was -1%. Furthermore, the
linearity of the RQ-TRAP assay with respect to the
non-HI cell lysate of a sample was verified by per-
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Figure 2 Cycle thresholds (Ct) for telomerase activity following serial dilution of the cell extracts.
forming a standard curve using serial dilutions (1, 0.5,
and 0.25 mL template volume). R2 between 0.871 and
0.999 were obtained (Figure 2). Most importantly,
comparable levels of telomerase activity were detect-
ed in frozen cell extracts (q10 days, and 1-year BC)
as compared to those stored at 48C, thus demonstrat-
ing the robustness and utility of the RQ-TRAP protocol
used for the detection of telomerase activity in circu-
lating leukocytes. This shows the feasibility of this
technique in population (epidemiological) based
settings for disease association/prediction.
Discussion
The majority of published studies on the determina-
tion of telomerase activity emphasize immediate
preparation of samples. Often times, immediate pre-
paration of cell extracts is not feasible in blood spec-
imens routinely collected in clinical/epidemiological
settings due to logistic/delivery considerations.
Hence, the present observations provide evidence
that there is no observable reduction in telomerase
activity following long-term storage at –808C. In fact,
it is generally believed that telomerase activity is par-
ticularly labile due to degradation of the RNA com-
ponent (10–12). Our data show that if leukocytes/buffy
coats are isolated, stored and processed as described,
telomerase activity is not significantly affected. There-
fore, this assay provides the opportunity to evaluate
archived frozen samples, as well as prospectively
collected samples.
The TRAP-ELISA technique allowed for an increase
in the sensitivity of telomerase activity measure-
ments, enabling the detection of low levels in un-
stimulated somatic cells such as leukocytes (4–7).
However, the RQ-TRAP assay is quantitative, corre-
lates with TRAP-ELISA (9) and lends itself to high-
throughput screening and analysis. There is no
consensus on the units that best represent telomerase
activity. Units such as ‘‘arbitrary units’’ (13), ‘‘per-
centages’’ (9, 14), ‘‘absorbance ratios’’ (15), ‘‘relative
activity’’ (16), and undefined ‘‘units’’ or ‘‘activity’’ (17,
18) have been used by various authors to describe
telomerase activity. Our results are presented as Ct to
allow for comparability with the original study report-
ed by Wege et al. (9). Using this format, an increase
in Ct levels represents a decrease in telomerase
activity.
In conclusion, the present study demonstrates the
utility of the SYBR Green high-sensitivity RQ-TRAP
assay for the detection and quantification of very low
basal levels of telomerase activity in circulating
human leukocytes. It also suggests the feasibility of
this method for screening blood samples routinely
collected in clinical/epidemiological studies for telo-
merase activity.
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